You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

mass. movers

Drug maker slides after trial disappoints

Merrimack’s drug testing targeted a type of  ovarian cancer.

istockphoto.com

Merrimack’s drug testing targeted a type of ovarian cancer.

Continue reading below

Merrimack Pharmaceuticals Inc., a Cambridge company focused on developing cancer therapies, fell after it reported results from a mid-stage study involving the drug MM-121 in combination with Paclitaxel to treat platinum-resistant or refractory-advanced ovarian cancer. MM-121, being developed with Sanofi, did not meet its primary “endpoint” of improving progression-free survival. There was no statistical difference between MM-121 with Paclitaxel and Paclitaxel alone. Side effects like diarrhea and vomiting were more prevalent in the group taking MM-121.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.